Abstract 51P
Background
STING (STimulator of INterferon Genes) is a pattern recognition receptor detecting cytoplasmic nucleic acids and transmits signals that activate host innate immune responses. It has been found to be involved in anti‐microbial immunity, autoimmune disorder and tumorigenesis. Thus, the acknowledgement of the cellular regulation of STING is important. However, transcriptional regulation of STING and its role in tumor development has not been reported.
Methods
STNF expressing vector was constructed and used to identify the STNF regulatory function of STING. Small interfering RNA was used to silence STNF expression. For the first time, full length of STING promoter was constructed with luciferase reporter which enabled quick and semi-quantitative of STING promoter activity. The bc-GenExMiner v4.2 database was used to evaluate the expression and prognostic merit of STNF and STING in breast cancer (BC). Western blot, RT-qPCR and CCK-8 assay were used to detect STING expression and BC cell growth.
Results
We have identified a novel negative regulator of STING (STNF). The effect of STNF appeared to be at the transcriptional level of STING since STNF could suppress the promoter activity of STING. STNF was up-regulated in breast cancer (BC) and associated with poor prognosis of BC patients. Silencing STNF or pharmacologically inhibiting STNF promoted STING expression and suppressed BC growth. STING down-regulation was observed in different types of BC and restoration of STING expression resulted in broad BC inhibition.
Conclusions
Our study demonstrated an unprecedented strategy used by breast tumor to escape from STING mediated tumor suppression. The identification of a novel STING regulator will provide insights for novel anti-tumor strategy against BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiao-Fang Yu.
Funding
National Youth Science Fund Project: 81701988(C0025181).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract